NASDAQ: ALVOAlvotech Stock
$13.27+0.04 (+0.3%)
Updated Jan 17, 2025
ALVO Price
$13.27
Fair Value Price
N/A
Market Cap
$3.71B
52 Week Low
$9.15
52 Week High
$18.00
P/E
-7.17x
P/B
-10.79x
P/S
8.44x
PEG
N/A
Dividend Yield
N/A
Revenue
$393.92M
Earnings
-$441.45M
Gross Margin
59%
Operating Margin
-21.55%
Profit Margin
-112.1%
Debt to Equity
-4.59
Operating Cash Flow
-$189M
Beta
0.15
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ALVO Overview
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ALVO's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
C
Value
A
Growth
C
Momentum
A
Sentiment
C
Safety
D
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
ALVO
Ranked#21 of 63
Ranked#21 of 63
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $37.74 | A | |
| $20.82 | A | |
| $14.41 | A |
Be the first to know about important ALVO news, forecast changes, insider trades & much more!
ALVO News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ALVO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ALVO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ALVO is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
ALVO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more ALVO due diligence checks available for Premium users.
Valuation
ALVO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-7.17x
Industry
4.69x
Market
30.45x
ALVO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-10.79x
Industry
2.24x
ALVO's financial health
Profit margin
Revenue
$103.0M
Net Income
-$11.4M
Profit Margin
-11.1%
ALVO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ALVO's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.2B
Liabilities
$1.6B
Debt to equity
-4.59
ALVO's short-term assets ($432.61M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ALVO's long-term liabilities ($1.42B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ALVO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ALVO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$61.0M
Investing
$22.8M
Financing
$155.8M
ALVO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ALVO vs Pharmaceutical Stocks
Alvotech Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.